Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DD-01
- Development stage
- Phase 2
- Lead developer
- D&D Pharmatech
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
DD-01 is a long-acting, pegylated, dual agonist of the glucagon-like peptide-1 (GLP-1) receptor and glucagon receptor (GCGR). It is developed by D&D Pharmatech for the treatment of severe obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), and non-alcoholic steatohepatitis (NASH). DD-01 is administered via subcutaneous injection and has shown rapid reductions in liver fat and improvements in glycemic control.
- Other names
- DD01DD-01DD 01
02
Targets
GLP1R (GLP-1R)GCGR (Glucagon receptor)
Beyond the preview
Go deeper on DD-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DD-01.